Share price movements

On January 31, Aveo Pharmaceuticals (AVEO) issued a press release announcing its decision not to file an NDA (new drug application) for its drug, Fotivda (tivozanib), based on preliminary results from the Phase 3 trial, TIVO-3. Aveo Pharmaceuticals decided to submit an NDA for the drug with more mature data.

After the news, Aveo Pharmaceuticals’ share price fell by 60.49% and closed at $1.07 on January 31. The company closed at a discount of 50.04%—compared to its 52-week low price of $1.40. Aveo Pharmaceuticals closed at a discount of 80.52%—compared to its 52-week high price of $3.59.

Based on the closing price on January 31, Aveo Pharmaceuticals reported returns of -59.57% in the last week, -56.29% in the last month, and -71.45% in the last quarter. Aveo Pharmaceuticals reported returns of -67.16% in the last half year, -76.84% in the last year, and -56.29% YTD.

Based on Aveo Pharmaceuticals’ closing price on January 31, the broader small-cap market, represented by the iShares Core S&P Small-Cap ETF (IJR), reported returns of 2.34% in the last week, 10.63% in the last month, and 0.45% in the last quarter. Aveo Pharmaceuticals also reported returns of -10.99% in the last half year, -3.13% in the last year, and 10.63% year-to-date.

Based on the closing price on January 31, Aveo Pharmaceuticals has significantly underperformed IJR.

Aveo Pharmaceuticals has a market capitalization of $83.77 million. The company is a micro-cap stock. Aveo Pharmaceuticals might be riskier compared to the broader stock market and large-cap stocks for retail investors.

Aveo Pharmaceuticals Stock Fell More than 60% on January 31

Analysts’ recommendations and target price

On February 1, analysts’ 12-month consensus recommendation for Aveo Pharmaceuticals is a “buy.” The company’s 12-month consensus target price is $5, which is 614.90% higher than the closing price on January 31. Aveo Pharmaceuticals’ highest, median, and lowest target price is $9, $4, and $3, respectively

Among the four analysts covering Aveo Pharmaceuticals on February 1, one recommended a “strong buy,” while three recommended a “buy.”

Latest articles

Apple stock fell 4.6% as the US-China trade war intensified today. China warned of tariffs on more US goods, followed by Trump's tweeted response.

In response to new tariffs from China and President Trump's tweets, the market tanked to session lows on Friday. The DJIA nosedived more than 600 points.

Coverage on Cresco Labs has increased from seven analysts in July to nine in August. Six analysts favor a “strong buy,” and three recommend a “buy.”

AMD stock hit a new 13-year high after the EPYC Rome server CPU launched. How can AMD outperform Intel CPUs at such low prices and still profit?

VMware (VMW) lost about 9% in early hours trading today. VMW released its Q2 of fiscal 2020 results on August 22 after the market closed.

Since Netflix posted its Q2 results, its stock has fallen 18%. Could the streaming giant lose its disruptor position as new players enter the market?